Recurrent Non-small Cell Lung Cancer Completed Phase 2 Trials for Sorafenib (DB00398)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00098540Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment